Changes in Hong Kong stocks | Insili Intelligence (03696) rose more than 7% in early trading to develop AI-driven drug discovery cooperation with Kangzhe Pharmaceutical in the field of central nervous system

The Zhitong Finance App learned that Insili Intelligence (03696) rose more than 7% in early trading. As of press release, it had risen 6.45% to HK$45.58, with a turnover of HK$178 million.

According to news, on July 13, the company announced another AI-driven drug discovery cooperation with Kangzhe Pharmaceutical (00867) in the central nervous system field, according to the official WeChat account of Insili Intelligence. The collaboration targets the indications of a huge market and is based on innovative mechanisms of action (MoA) identified by PandaOmics.

According to the cooperation agreement, the two sides will combine the AI platform proven by Insili Intelligence with AI to enable innovative drug research and development capabilities, as well as Kangzhe Pharmaceutical's experienced R&D team and deep knowledge in the field of diseases, and the two sides will jointly promote the cooperative development of this R&D project. At the same time, Insili Smart is expected to receive a total milestone payment of up to about RMB 1.2 billion and a share of net sales. This cooperation marks a further deepening of the relationship between the two sides and aims to give full play to the complementary advantages of the two sides in the entire value chain of drug discovery, clinical development and commercialization.